- Indication: Cutaneous Lupus Erythematosus
- Enrollment Status: Pre-Enrollment
- Protocol: IMVT-1402-2701
- Drug: IMVT-1402
- Sponsor: Immunovant
- Description: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants with Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations
